Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine in Refractory/Relapsed T-Lineage ALL or LBL
NCT00003545Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 1998
- Primary completion
- Mar 2007
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nelarabine in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by National Cancer Institute. Started Aug 1998; status: completed.
02
Drugs
nelarabine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT00003545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003545.